|
Title
|
Status
|
|
|
Recruiting
in 4 of 4 locations
|
|
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in
different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer
growth in different ways. Some block the ability of cancer cells to grow and spread. Others
find cancer cells and help kill them or carry cancer-killing substances to them.
Lenalidomide may stimulate the immune system in different ways and stop cancer cells from
growing. Giving fludarabine and rituximab together with lenalidomide or cyclophosphamide may
kill more cancer cells.
PURPOSE: This randomized phase II trial is studying fludarabine and rituximab to compare how
well they work with or without lenalidomide or cyclophosphamide in treating patients with
symptomatic chronic lymphocytic leukemia.
|
|
|
Recruiting
in 1 of 1 locations
|
|
This is a phase II, non-randomized, single institution study in symptomatic, previously untreated CLL patients. All patients will receive the study drug, lenalidomide, given PO daily continuously on a 28 day cycle at the starting dose level of either 2.5 mgs or 5 mgs with dose escalations to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle. Patients will be treated with lenalidomide and dexamethasone to 2 cycles past CR or to a maximum of 18 cycles. Primary endpoint is response.
|
|
|
Recruiting
in 1 of 1 locations
|
|
This study is a Phase III, randomized, open-label, multi-center, prospective study of single
umbilical cord blood (UCB) transplantation versus double UCB transplantation in pediatric
patients with hematologic malignancies.
|
|
|
Recruiting
in 2 of 2 locations
|
|
The purpose of this study is to determine the safety and effectiveness of different dose
regimen of lenalidomide in patients with relapsed or refractory chronic lymphocytic
leukemia.
|
|
|
Recruiting
in 3 of 3 locations
|
|
The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the duration of your response. This study will compare the effects (good and bad) of lenalidomide with the dummy drug.
|
|
|
Recruiting
in 3 of 4 locations
|
|
The purpose of this study is to evaluate the safety and efficacy of ofatumumab added to fludarabine-cyclophosphamide in patients with relapsed Chronic Lymphocytic Leukemia.
|
|
|
Recruiting
in 0 of 3 locations
|
|
RATIONALE: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) and pilocarpine may help to relieve chronic xerostomia (dry mouth). It is not yet known which remedy is more effective in treating chronic dry mouth caused by radiation therapy in patients with head and neck cancer. PURPOSE: This randomized phase II/III trial is studying ALTENS to see how well it works compared with pilocarpine in treating chronic dry mouth caused by radiation therapy in patients with head and neck cancer.
|
|
|
Recruiting
in 1 of 1 locations
|
|
This is an open-label, single arm phase 1 study to evaluate the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of Clioquinol in patients with relapsed or refractory hematologic malignancies. The study will also characterize Cliquinol's safety, tolerability and pharmacodynamic effect.
|
|
|
Recruiting
in 1 of 1 locations
|
|
OBJECTIVES
To investigate:
- the mechanism of Valproic Acid (VPA)-induced apoptosis in B-CLL
- the ability of VPA in combination with standard chemotherapy or new antitumor agents to
induce a synergistic antitumor effect in chronic lymphocytic leukemia (CLL) cells
- the clinical efficacy of VPA in previously treated CLL patients.
This will be an example of a translational research study where the results of our
laboratory studies will be applied to a clinical trial in the CLL clinic at CancerCare
Manitoba.
|
|
|
Recruiting
in 4 of 8 locations
|
|
RATIONALE: Implant radiation therapy uses radioactive material placed directly into or near
a tumor to kill tumor cells.
PURPOSE: This phase II trial is studying the side effects and how well ultrasound-guided
implant radiation therapy works in treating patients with locally recurrent prostate cancer
previously treated with external-beam radiation therapy.
|
